STCube, Inc.
π°π·South Korea
- Country
- π°π·South Korea
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.stcube.com
Nelmastobart in Combination with Trifluridine/Tipiracil and Bevacizumab in Metastatic/Recurrent Colorectal Cancer
Phase 1
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer (CRC)Recurrent Colorectal Cancer
- Interventions
- Drug: Nelmastobart 800 mg+Trifluridine/Tipiracil+ Bevacizumab
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- STCube, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT06873763
- Locations
- π°π·
Korea University Anam Hospital, Seoul, Korea, Republic of
A Study of hSTC810 in Combination With Paclitaxel in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer
Phase 1
Recruiting
- Conditions
- Extensive Stage Small Cell Lung Cancer
- Interventions
- Drug: hSTC810 400 mg + PaclitaxelDrug: hSTC810 800 mg + Paclitaxel
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- STCube, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT06016270
- Locations
- π°π·
Seoul National University Bundang Hospital, Seoul, Korea, Republic of
π°π·The Catholic University of Korea St. Vincent's Hospital, Suwon, Korea, Republic of
πΊπΈMD Anderson Cancer Center, Houston, Texas, United States
A Study of hSTC810 With Advanced/Metastatic Solid Tumors (STCUBE-001)
Phase 1
Completed
- Conditions
- Advanced Solid Tumor
- Interventions
- Biological: hSTC810
- First Posted Date
- 2022-02-09
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- STCube, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT05231746
- Locations
- π°π·
Yonsei University Severance Hospital, Seoul, Korea, Republic of
π°π·Korea University Anam Hospital, Seoul, Korea, Republic of
πΊπΈMount Sinai Hospital, New York, New York, United States
Β© Copyright 2025. All Rights Reserved by MedPath